Congenital Myasthenic Syndrome 7 (CMS7 / SYT2-Related Presynaptic Myasthenia): A Comprehensive Disease Characterization

MONDO: MONDO:0014468 · OMIM: #616040 (CMS7A, dominant) / #619461 (CMS7B, recessive) · Gene: SYT2 (synaptotagmin-2) · Category: Mendelian, rare

Summary

Congenital Myasthenic Syndrome 7 (CMS7) is an ultra-rare, genetically determined presynaptic disorder of neuromuscular transmission caused by germline variants in SYT2 (synaptotagmin-2), the protein that serves as the calcium sensor for fast, synchronous acetylcholine (ACh) release at the neuromuscular junction (NMJ). Because the primary lesion sits in the nerve terminal rather than the muscle endplate, CMS7 behaves clinically and electrophysiologically like a genetic mimic of the autoimmune Lambert–Eaton myasthenic syndrome (LEMS): low compound muscle action potential (CMAP) amplitudes at rest that facilitate (increment) after brief exercise or high-frequency stimulation, together with a characteristically prolonged post-tetanic potentiation. The disease is important out of proportion to its rarity because it is treatable — patients respond to the potassium-channel blocker 3,4-diaminopyridine (3,4-DAP) and to acetylcholinesterase inhibitors such as pyridostigmine.

CMS7 has two inheritance modes with distinct severity. Autosomal dominant disease arises from heterozygous missense or in-frame variants clustered in the C2B calcium-binding domain (canonically p.Asp307Ala and p.Pro308Leu), which act by a dominant-negative mechanism; these patients present with slowly progressive or non-progressive distal lower-limb weakness and wasting, foot deformities (pes cavus), fatigable weakness, hyporeflexia/areflexia with post-exercise reflex potentiation, and a phenotype that can mimic a distal hereditary motor neuropathy/Charcot–Marie–Tooth disease. Autosomal recessive disease arises from biallelic loss-of-function variants (frameshift, nonsense, splice-site, large deletion), frequently in consanguineous families, and is substantially more severe — congenital-onset hypotonia, profound weakness, areflexia, bulbar dysfunction, and variable respiratory involvement.

This report synthesizes 13 confirmed findings drawn from 29 papers, including the seminal disease-gene reports (Herrmann 2014, Whittaker 2015), recessive-form descriptions (2019–2021), a Drosophila causality model, comprehensive CMS reviews (35- and 40-gene reviews), UK epidemiology, and gnomAD constraint analysis. Across the sections below, CMS7 is characterized at the level of disease identity, etiology, phenotype, molecular genetics, pathophysiology (presented as an explicit causal chain), affected anatomy, temporal course, inheritance/population genetics, diagnostics, prognosis, treatment, prevention, and model organisms. Where information is genuinely unavailable for this ultra-rare disease (e.g., formal quality-of-life instrument data, natural-history registries specific to SYT2), this is stated explicitly.

1. Disease Information

What it is. CMS7 is a Mendelian congenital myasthenic syndrome in which fast synchronous neurotransmitter release at the NMJ fails because of defects in the presynaptic calcium sensor synaptotagmin-2. It is one of the small group of presynaptic CMS subtypes that phenocopy LEMS (the "CMS-LEMS" group), alongside AGRN, MUNC13-1/UNC13A, VAMP1, and LAMA5 (F004; PMID: 29696584).

Key identifiers.

Synonyms / alternative names. CMS7; SYT2-related disease; SYT2-CMS; presynaptic congenital myasthenic syndrome 7; autosomal-dominant Lambert-Eaton–like myasthenic syndrome with nonprogressive motor neuropathy (dominant form). Gene aliases: CMS7, CMS7A, CMS7B, MYSPC, SytII (F008).

Data provenance. Essentially all knowledge derives from aggregated disease-level resources and individual published case reports/small case series (~10–15 families worldwide), not from EHR/population phenotyping — a direct consequence of the disease's extreme rarity.

2. Etiology

Primary cause — genetic. CMS7 is a monogenic disorder caused entirely by pathogenic germline variants in SYT2. There is no environmental, infectious, or acquired etiology; it is not autoimmune (distinguishing it mechanistically from myasthenia gravis and from paraneoplastic LEMS). Two allelic mechanisms operate (F001, F010):

• Dominant heterozygous C2B-domain missense/in-frame variants → dominant-negative poisoning of release.
• Recessive biallelic loss-of-function variants → absence of functional SYT2.

Genetic risk factors. The causal variants themselves are the risk factor. For the recessive form, consanguinity is a major contributing factor (multiple reported homozygous cases in consanguineous families; F010; PMID: 32250532, PMID: 36722210). No susceptibility loci, GWAS signals, or modifier genes have been established for this Mendelian disease.

Environmental / lifestyle / protective factors. None established. As a channel/release Mendelian disorder, there are no known dietary, occupational, toxic, or lifestyle risk or protective factors, and no gene–environment interactions have been reported. (Not applicable / not available.)

Infectious agents. Not applicable — CMS7 is non-infectious. Intercurrent respiratory infections can precipitate crises in the severe recessive form (a trigger of morbidity, not a cause).

3. Phenotypes

CMS7 phenotypes are clinical signs and physical manifestations of impaired neuromuscular transmission plus a secondary neurogenic/motor-neuropathy component. Severity is bimodal by inheritance mode (F005).

Key supporting evidence (F005): a 2025 case-based review synthesizing 28 cases describes SYT2-related disease as "characterized by distal muscle atrophy in the lower limbs, foot deformities and, in some cases, neonatal hypotonia," with most mutations in the C2B domain (PMID: 41331967). The dominant-vs-recessive severity gradient is explicit: "The recessive form of CMS caused by a SYT2 mutation showed far more severe clinical manifestations than the dominant form" (PMID: 34037996). Distal weakness with pes cavus can mimic distal hereditary motor neuropathy/CMT (PMID: 33320396).

Quality-of-life impact. No disease-specific EQ-5D/SF-36/PROMIS data exist for CMS7 (not available). Qualitatively, the dominant form causes gait impairment and fatigue affecting mobility and daily function; the recessive form causes major disability with respiratory and feeding needs. A salbutamol trial in NMJ-involving motor neuropathies (including SYT2) recorded patient-reported fatigue as a meaningful endpoint (F007; PMID: 36869887).

4. Genetic / Molecular Information

Causal gene. SYT2 (synaptotagmin-2), HGNC:11510, NCBI Gene 127833, Ensembl ENSG00000143858, UniProt Q8N9I0, chromosome 1q32.1 (GRCh38 chr1:202,590,596–202,710,526, minus strand) (F008).

Protein architecture. Synaptotagmin-2 is a synaptic-vesicle transmembrane protein with an N-terminal intravesicular/luminal region, a single transmembrane domain, and two cytoplasmic tandem C2 domains (C2A and C2B) that bind Ca²⁺ and phospholipids/SNAREs (F008). SYT2 is the major synaptotagmin isoform at the human NMJ and one of only three (SYT1, SYT2, SYT9) that serve as Ca²⁺ sensors for fast synchronous release (F002; PMID: 17521570).

Pathogenic variants and their mechanisms.

Variant classification & population frequency. Reported pathogenic variants are private/ultra-rare and effectively absent or singleton in population databases, consistent with high penetrance and de novo/consanguineous origins (F013). gnomAD constraint for SYT2 (F013): pLI = 0.70, LOEUF (upper) = 0.58, LoF-z = 3.34 (intolerant to complete LoF), missense-z = 2.62 (missense-constrained), synonymous-z = 0.98 (neutral, as expected). This constraint profile explains why dominant missense variants are pathogenic and why biallelic LoF produces severe disease.

Somatic vs germline. All variants are germline. No somatic disease role.

Functional consequences. Dominant C2B missense/in-frame variants = dominant-negative; recessive truncating/splice/structural variants = loss of function (F008, F010; PMID: 34037996, PMID: 32776697).

Modifier genes / epigenetics / chromosomal abnormalities. No modifier genes, epigenetic marks, or large chromosomal abnormalities (beyond the single-gene exonic deletion above) are established for CMS7 (not available). One mechanistic aside: in cortical neurons, calmodulin transcriptionally suppresses SYT2, an inverse rostral–caudal expression relationship — relevant to SYT2 biology but not established as a disease modifier (PMID: 20729199).

5. Environmental Information

Environmental, lifestyle, and infectious factors. Not applicable to disease causation — CMS7 is purely Mendelian. There are no reported toxin, radiation, occupational, dietary, smoking, alcohol, or exercise contributions to disease risk. Intercurrent respiratory infections are clinically relevant only as precipitants of crisis/morbidity in the severe recessive form, not as etiologic agents (F012; PMID: 41331967).

6. Mechanism / Pathophysiology

Causal chain (initiating lesion → clinical manifestation)

Dominant (C2B missense/in-frame) branch: 1. Heterozygous C2B-domain missense/in-frame variant in SYT2 (e.g., p.Asp307Ala disrupting an essential Ca²⁺-coordinating aspartate) produces a mutant synaptotagmin-2 protein that still incorporates into the release machinery. 2. The mutant protein acts dominant-negatively, poisoning the Ca²⁺-sensing/SNARE-coupling function of the release apparatus even in the presence of one wild-type allele (demonstrated in Drosophila, where co-expression with one wild-type copy reproduces disease) → impaired coupling of Ca²⁺ influx to synchronous synaptic-vesicle fusion. 3. This results in reduced quantal content (fewer ACh quanta released per nerve impulse), most evident at low stimulation frequencies. 4. Reduced ACh release leads to an endplate potential that intermittently fails to reach threshold → intermittent neuromuscular transmission failure → fatigable weakness. 5. Because residual Ca²⁺ accumulates in the terminal during repetitive/high-frequency activity, release transiently improves → facilitation/post-exercise increment and prolonged post-tetanic potentiation (the LEMS-like signature). 6. Chronic presynaptic dysfunction is associated with a secondary distal motor neuropathy/terminal remodeling → distal wasting, pes cavus, areflexia → the clinical phenotype.

Recessive (biallelic LoF) branch: 1. Biallelic loss-of-function variants (frameshift/nonsense/splice/deletion) result in absent or non-functional SYT2 protein. 2. Loss of the principal fast Ca²⁺ sensor leads to profound impairment of synchronous ACh release (more severe presynaptic failure than the dominant form). 3. This results in congenital-onset severe weakness, hypotonia, bulbar and respiratory compromise. (The C-terminal recessive variant p.Arg397Serfs37 disrupts a region crucial for synaptotagmin–SNARE interaction and exocytosis — inferred from structural modeling on the rat Syt1 C2B template.)*

Molecular / cellular detail (checklist)

• Molecular pathways / biochemical defect. Ca²⁺-triggered synaptic-vesicle exocytosis; SYT2 is the Ca²⁺ sensor that couples voltage-gated Ca²⁺ influx to SNARE-mediated membrane fusion. The core defect is an ion-sensor/receptor-coupling failure, not an enzyme deficiency (F002; PMID: 17521570). Suggested GO: GO:0016079 (synaptic vesicle exocytosis), GO:0017156 (calcium-ion-regulated exocytosis), GO:0005544 (calcium-dependent phospholipid binding).
• Cellular processes. Presynaptic vesicle fusion, endocytic recycling, and — in the recessive form — ultrastructural remodeling of the nerve terminal (F006).
• Protein dysfunction. Dominant = dominant-negative interference; recessive = loss of function. C2B Ca²⁺-binding-pocket modeling (SwissModel) predicts structural disruption for pathogenic variants (F009; PMID: 33320396, PMID: 28953919).
• Metabolic / immune involvement. None — no metabolic derangement and no autoimmunity (ACh-receptor and VGCC antibodies negative), which distinguishes CMS7 from MG and autoimmune LEMS (F011).
• Molecular profiling (electrophysiology & ultrastructure). Microelectrode studies in the dominant form show markedly reduced quantal content that increases linearly with higher stimulation frequencies; MEPP frequency is normal at rest but rises with stimulation. Electron microscopy shows overdeveloped postsynaptic folding and abundant endosomes, multivesicular bodies, and degenerative lamellar bodies within small nerve terminals; presynaptic failure is more prominent in the recessive form (F006; PMID: 34037996).

Upstream vs downstream. Upstream = SYT2 variant → defective Ca²⁺-sensing/SNARE coupling. Downstream = reduced quantal ACh release → EPP failure → fatigable weakness, with facilitation as a distinctive downstream compensatory readout, and secondary distal neuropathy/terminal remodeling as a chronic downstream consequence.

Cell types & CL terms. Presynaptic motor neuron / lower motor neuron terminal (CL:0000100 motor neuron; CL:0011001 spinal cord motor neuron) and the skeletal muscle fiber (CL:0000188) postsynaptic partner.

7. Anatomical Structures Affected

• Organ / system level. Primary target is the peripheral nervous system–muscle interface: the neuromuscular junction (UBERON:0002476, neuromuscular junction; GO:0031594 neuromuscular junction as a cellular component). Body systems: somatic motor / musculoskeletal and, secondarily, respiratory (respiratory muscle involvement in severe recessive disease) and bulbar musculature.
• Tissue / cell level. Skeletal (striated) muscle (UBERON:0001134) and the presynaptic motor neuron terminal. Predominant clinical involvement is distal lower limb in the dominant form; generalized/axial and bulbar/respiratory in the recessive form.
• Subcellular level. Synaptic vesicle and presynaptic active zone membranes (GO:0008021 synaptic vesicle; GO:0048786 presynaptic active zone). Ultrastructurally, endosomes, multivesicular bodies, and lamellar bodies accumulate in nerve terminals (F006).
• Localization / lateralization. Symmetric, bilateral involvement; distal-predominant in the dominant form. Specific sites: lower-limb muscles and feet (pes cavus). UBERON: UBERON:0002103 (hindlimb), UBERON:0002387 (pes/foot).

8. Temporal Development

• Onset. Congenital / neonatal in the recessive form (hypotonia, weak cry, feeding/respiratory problems from birth); childhood-onset distal weakness typical in the dominant form, with some presentations recognized later. Onset pattern is chronic/insidious rather than acute (F005, F012).
• Progression. Dominant form: stable or slowly progressive, described in the seminal report as a "nonprogressive motor neuropathy" and in the biallelic series as "stable or slowly progressive distal weakness of variable severity" (F012; PMID: 25192047, PMID: 32776697). Recessive form: severe from birth with variable respiratory course.
• Course pattern & duration. Chronic, lifelong, with a fluctuating/fatigable functional pattern superimposed on a stable structural baseline. No spontaneous remission is described; symptomatic improvement is treatment-induced (3,4-DAP, AChE inhibitors).
• Critical periods. The neonatal/infantile period is the window of greatest vulnerability (respiratory failure risk) and the key window for diagnosis and initiation of treatment in the severe recessive form.

9. Inheritance and Population

Epidemiology. CMS7/SYT2-CMS is ultra-rare. Genetically confirmed CMS overall prevalence is estimated at 6.5 per million overall and 8.5 per million in the pediatric population in the UK (n=442 cohort; F004; PMID: 41251564), with an earlier estimate of 9.2 per million (PMID: 34736634). The most common CMS subtypes are CHRNE, DOK7, and RAPSN; SYT2-CMS is one of the rarest presynaptic subtypes, with only ~10–15 families reported worldwide across dominant and recessive forms (F004). No incidence figures are available specifically for CMS7.

Inheritance genetics (F010, F013).

De novo dominant occurrence is documented ("a new de novo heterozygous in frame deletion of the SYT2 gene"; PMID: 33320396). Recessive disease is documented across multiple consanguineous families ("we report seven patients of five families, with biallelic loss of function variants in SYT2"; PMID: 32776697).

Penetrance, expressivity, anticipation, mosaicism, founder effects. Penetrance appears high; expressivity is variable (severity gradient by allele type). No genetic anticipation (not a repeat-expansion disorder). No germline mosaicism or founder effects reported. Carrier frequency is not quantifiable — pathogenic variants are absent/singleton in gnomAD (F013).

Population demographics. No ethnic predilection beyond the association of the recessive form with consanguineous populations. No sex bias reported; both sexes affected (autosomal). Geographic distribution: cases reported across Europe, the Middle East, and Asia — sporadic, without endemic clustering.

10. Diagnostics

Diagnosis integrates presynaptic electrophysiology with molecular genetics (F011).

Electrophysiology (the diagnostic hallmark). Repetitive nerve stimulation (RNS) shows low baseline CMAP amplitude, a decremental response at low frequency, and a marked increment/facilitation after brief exercise or high-frequency stimulation, with prolonged post-tetanic potentiation lasting up to ~60 minutes and single-fiber EMG jitter/blocking — a LEMS-like presynaptic signature (F006, F011; PMID: 26519543: "Electrophysiologic testing revealed features indicative of a presynaptic deficit in neurotransmitter release with posttetanic potentiation lasting up to 60 minutes"; PMID: 29696584: "They have low compound muscular action potential amplitude that increment after brief exercise (facilitation) or high-frequency repetitive nerve stimulation").

Laboratory. CK normal or mildly elevated (e.g., 501 U/L; PMID: 41331967). ACh-receptor and VGCC antibodies negative — critical for excluding autoimmune MG/LEMS.

Genetic testing. SYT2 is identified via whole-exome sequencing and multigene CMS/neuromuscular NGS panels, with Sanger confirmation; chromosomal microarray/exome can detect large exonic deletions (the exons 2–9 deletion; PMID: 36722210). Because CMS is now attributable to ~40 genes, panel/exome testing is the standard first-line molecular approach (PMID: 40533459, PMID: 36835142). Single-gene SYT2 testing is appropriate when the LEMS-like presynaptic phenotype is recognized. WGS is useful for deep-intronic/structural variants when panel/exome is negative. Mitochondrial DNA testing, karyotyping, FISH, and repeat-expansion testing are not indicated.

Muscle biopsy / pathology. Typically shows only mild/nonspecific neurogenic features; EM (research setting) shows the terminal remodeling described above (F006; PMID: 33320396).

Differential diagnosis. Autoimmune LEMS (antibody-positive, often paraneoplastic); other presynaptic CMS (AGRN, VAMP1, UNC13A/MUNC13-1, LAMA5, SLC5A7, SLC18A3); distal hereditary motor neuropathy / Charcot–Marie–Tooth; spinal muscular atrophy; and congenital myopathies (F011; PMID: 29696584, PMID: 33320396).

Screening. No population newborn screening exists for CMS7. Cascade genetic testing of relatives and, where a familial variant is known, prenatal/preimplantation options apply.

11. Outcome / Prognosis

• Survival / mortality. No formal survival statistics exist. The dominant form is compatible with normal life expectancy. In the severe recessive form, respiratory insufficiency and recurrent respiratory infections are the principal drivers of morbidity and potential mortality (F012; PMID: 41331967, PMID: 32776697).
• Morbidity / function. Dominant form: mobility limitation from distal weakness and foot deformity, fatigue. Recessive form: major disability with feeding/respiratory support needs in infancy.
• Disease course & recovery. Symptoms are chronic; substantial functional improvement is achievable with treatment even in severe recessive disease — "Treatment with an acetylcholinesterase inhibitor pursued in three patients showed clinical improvement with increased strength and function" (PMID: 32776697).
• Prognostic factors. The strongest prognostic determinant is allele class / inheritance mode (dominant missense = milder; biallelic LoF = severe), followed by degree of respiratory involvement and treatment responsiveness. No molecular prognostic biomarkers beyond genotype.

12. Treatment

CMS7 is treatable, and — as in CMS generally — the choice of agent is subtype-specific (F003; PMID: 30032336). There is no role for immunotherapy (it is not autoimmune).

Mechanistically, 3,4-DAP is the rational first-line agent for a presynaptic release deficit because it augments Ca²⁺ influx and quantal release; AChE inhibitors are a useful adjunct/alternative. The pharmacologic logic mirrors treatment of LEMS. Broader CMS treatment principles: "Cholinergic agents, β-adrenergic agonists, and open-channel blockers remain the principal treatment modalities," and pyridostigmine should be avoided in DOK7, AChE deficiency, and slow-channel CMS — underscoring the necessity of an accurate genetic diagnosis before treatment (PMID: 30032336).

Supportive / rehabilitative. Respiratory support and infection management (severe recessive disease), physical/occupational therapy, orthotic management of foot deformities, and nutritional/feeding support in infancy.

Advanced/experimental therapeutics. None approved specifically for CMS7. No gene, cell, or RNA therapy exists. A research-stage delivery concept exploits SYT2's luminal domain: intravenously administered anti-SYT2 antibodies selectively localize to NMJs and are retrogradely transported to motor neurons — a potential future neuron-targeted delivery route rather than a CMS7 therapy (PMID: 40454418).

Pharmacogenomics / personalized medicine. Treatment is effectively genotype-guided at the level of CMS subtype (presynaptic → 3,4-DAP/AChE inhibitor). No SYT2-specific pharmacogenomic variants are described.

13. Prevention

CMS7 is a Mendelian disorder, so prevention is genetic, not behavioral or environmental.

• Primary prevention. Not applicable in the public-health sense. The relevant tools are genetic counseling, carrier testing of at-risk relatives (recessive form), and reproductive options — prenatal diagnosis and preimplantation genetic testing — where a familial pathogenic variant is known.
• Secondary prevention. Early recognition of the LEMS-like presynaptic electrophysiology → prompt genetic diagnosis → early initiation of 3,4-DAP/AChE inhibitors to prevent avoidable disability; vigilant respiratory monitoring and prompt treatment of respiratory infections in the severe recessive form.
• Tertiary prevention. Respiratory support, immunization against respiratory pathogens (influenza, pneumococcus) to reduce infection-triggered crises, orthopedic/rehabilitative management of contractures and foot deformities.
• Counseling. Recurrence risk is 50% for offspring of a dominant-variant carrier and 25% for siblings in recessive families; consanguinity counseling is relevant.

14. Other Species / Natural Disease

• Taxonomy / orthologs. SYT2 is evolutionarily conserved. Mouse Syt2 (NCBI Gene 20680) is the ortholog and is the major fast-release Ca²⁺ sensor in caudal brain/brainstem and motor neurons (F009; PMID: 17521570, PMID: 20729199). Drosophila melanogaster synaptotagmin is functionally orthologous for modeling purposes. NCBI Taxa: Mus musculus (10090), Drosophila melanogaster (7227).
• Natural disease in other species. No naturally occurring SYT2 congenital myasthenic syndrome has been reported in companion animals or wildlife (no OMIA entry noted); CMS7 is, to date, a human-described disease with experimental animal models rather than a recognized spontaneous veterinary disease. (Not available.)
• Comparative biology. The evolutionary conservation of synaptotagmin's Ca²⁺-sensor function underpins the validity of invertebrate and rodent models; the fly heterozygous model recapitulates the human dominant-negative phenotype (see Section 15).

15. Model Organisms

• Drosophila melanogaster (primary causality model). Expressing the human-homologous C2B mutation (P308-equivalent) in flies lacking native synaptotagmin was lethal, demonstrating the residue is critical for synaptotagmin function; co-expression with one wild-type copy (mimicking the heterozygous human state) produced neurological/behavioral manifestations similar to patients and dominant disruption of synaptic-vesicle exocytosis — directly establishing pathogenicity and the dominant-negative mechanism (F009; PMID: 28953919: "When expressed in the absence of native synaptotagmin, this mutation is lethal, demonstrating for the first time that this residue plays a critical role in synaptotagmin function" and "Drosophila carrying this mutation developed neurological and behavioral manifestations similar to those of human patients").
• Mouse (Syt2). The mouse ortholog is the validated fast-release Ca²⁺ sensor for brainstem/motor-neuron synapses (PMID: 17521570); Syt2-manipulated rodents inform normal SYT2 physiology, though a dedicated CMS7 patient-variant knock-in mouse is not prominently reported.
• In silico / structural modeling. C2B Ca²⁺-binding-pocket modeling (SwissModel; rat Syt1 C2B X-ray template) predicts structural disruption for pathogenic variants and supports variant interpretation (PMID: 33320396, PMID: 32250532).
• Phenotype recapitulation & limitations. The fly model faithfully reproduces the dominant-negative exocytosis defect and dominant inheritance; it does not capture the human distal motor-neuropathy/foot-deformity phenotype or the recessive LoF disease, and mammalian models specifically engineered with patient recessive alleles are lacking. Applications: dissecting Ca²⁺-sensing/SNARE coupling, dominant-negative mechanism, and candidate therapeutics.

Mechanistic Model / Interpretation

                 SYT2 (1q32.1) — Ca2+ sensor for fast synchronous ACh release
                                     |
        +----------------------------+-----------------------------+
   DOMINANT branch                                          RECESSIVE branch
   Heterozygous C2B missense/in-frame                  Biallelic LoF (fs/nonsense/
   (p.Asp307Ala, p.Pro308Leu, in-frame del)            splice/large deletion)
        |                                                       |
   Dominant-negative protein                               Absent/nonfunctional SYT2
   poisons release machinery                                   |
        |                                                       |
        +----------------> Impaired Ca2+->SNARE coupling <------+
                                     |
                     Reduced quantal ACh release per impulse
                                     |
                     Endplate potential intermittently subthreshold
                                     |
              +----------------------+-----------------------------+
      Fatigable weakness                          Facilitation / post-exercise
      (RNS decrement at low Hz)                    increment; prolonged PTP (~60 min)
                                     |
              Chronic terminal remodeling -> distal motor neuropathy
              (distal wasting, pes cavus, areflexia)
                                     |
      Dominant: milder, slowly progressive | Recessive: severe congenital,
      treatable (3,4-DAP, AChE inhibitors)  | bulbar/respiratory, treatable

The unifying concept is that CMS7 is a disorder of presynaptic quantal release in which allele class dictates severity: a poisoning (dominant-negative) mechanism produces a milder, distal, neuropathy-mimicking disease, while complete loss of the fast Ca²⁺ sensor produces severe congenital myasthenia. The facilitation phenomenon — pathognomonic on electrophysiology — is the direct downstream readout of residual Ca²⁺ rescuing release during repetitive activity, and it is precisely this mechanism that 3,4-DAP exploits therapeutically.

Evidence Base

All quoted snippets above are verbatim from the corresponding abstracts as recorded in the knowledge state (findings F001–F013).

Limitations and Knowledge Gaps

1. Extreme rarity → weak epidemiology. Only ~10–15 families are reported worldwide; there are no CMS7-specific prevalence/incidence figures, no natural-history registries, and no formal survival/QoL data. Prevalence is inferred from all-CMS studies.
2. No controlled treatment trials. Efficacy of 3,4-DAP and AChE inhibitors rests on case reports and small series, not randomized data. Salbutamol data are mixed and derive from a heterogeneous cohort.
3. Genotype–phenotype correlation incomplete. The dominant-negative vs LoF dichotomy is well supported, but finer correlations (specific variant → severity/organ involvement) remain anecdotal.
4. Model-organism gaps. Causality is proven in Drosophila; a mammalian knock-in carrying a patient dominant allele, and models of the recessive LoF disease, are lacking — limiting preclinical therapeutic testing.
5. No modifier/epigenetic data. No modifier genes, epigenetic marks, or environmental modifiers have been identified.
6. QoL/functional instruments unmeasured. No EQ-5D/SF-36/PROMIS or ICF-based disability data specific to CMS7.

Proposed Follow-up Experiments / Actions

1. International SYT2-CMS registry. Aggregate all reported and unpublished cases to derive genotype-stratified natural history, treatment-response rates, and survival — the single highest-value action given rarity.
2. Prospective, protocolized 3,4-DAP ± pyridostigmine response study. Standardized RNS/CMAP endpoints plus patient-reported fatigue to formalize the treatment evidence base (currently case-level).
3. Patient-variant knock-in mouse models. Generate C2B dominant-negative (e.g., p.Asp307Ala) and biallelic-LoF mice to reproduce distal neuropathy and severe congenital disease respectively, and to test therapeutics.
4. Structure-function dissection of C2B variants. Combine cryo-EM/AlphaFold modeling with electrophysiology in reconstituted or iPSC-derived motor-neuron/NMJ systems to map how each variant perturbs Ca²⁺ binding and SNARE coupling.
5. iPSC-derived motor neuron / NMJ-on-chip modeling. Patient-derived systems to screen candidate presynaptic-release enhancers beyond 3,4-DAP.
6. Explore SYT2-targeted delivery. Evaluate the anti-SYT2 luminal-domain NMJ-targeting antibody shuttle (PMID: 40454418) as a route for future gene- or protein-replacement approaches to the recessive LoF form.
7. Refine diagnostic pathways. Promote recognition of the LEMS-like presynaptic RNS signature in antibody-negative patients to shorten time-to-genetic-diagnosis and ensure SYT2 is on CMS/neuropathy NGS panels.

Report compiled from 13 confirmed findings (F001–F013) across 29 reviewed publications. Evidence types: predominantly human clinical case reports/series and comprehensive reviews, supplemented by a Drosophila causality model, rodent/in-vitro SYT2 physiology, and computational (gnomAD constraint, structural modeling) analyses.